CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Early versus delayed invasive intervention in acute coronary syndromes Association Between Collateral Circulation and Myocardial Viability Evaluated by Cardiac Magnetic Resonance Imaging in Patients With Coronary Artery Chronic Total Occlusion Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Risk Factors Associated With Major Cardiovascular Events 1 Year After Acute Myocardial Infarction Association of Silent Myocardial Infarction and Sudden Cardiac Death Management of Myocardial Revascularization Failure: An Expert Consensus Document of the EAPCI Coronary Artery Calcium Progression Is Associated With Coronary Plaque Volume Progression - Results From a Quantitative Semiautomated Coronary Artery Plaque Analysis

Original ResearchVolume 72, Issue 25, December 2018

JOURNAL:J Am Coll Cardiol. Article Link

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

A Ghorbani, V Bhambhani, RH Christenson et al. Keywords: Galectin-3; heart failure; biomarker; cardiovascular events; outcome; Framingham Heart Study Offspring cohort

ABSTRACT


BACKGROUND - Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.

 

OBJECTIVES - The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.

 

METHODS - A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3.

 

RESULTS - The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both).

 

CONCLUSIONS - Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.